{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:27:09Z","timestamp":1762522029321,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Guangdong Technology Project","award":["2014A020212119","2016A02021505","2014A020221009"],"award-info":[{"award-number":["2014A020212119","2016A02021505","2014A020221009"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81102270"],"award-info":[{"award-number":["81102270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2014A030313053","2016A030313217"],"award-info":[{"award-number":["2014A030313053","2016A030313217"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of China (CN)","award":["81603435"],"award-info":[{"award-number":["81603435"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40801-017-0112-y","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T05:25:43Z","timestamp":1498195543000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases"],"prefix":"10.1007","volume":"4","author":[{"given":"Liuqin","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donging","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"issue":"7","key":"112_CR1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","volume":"24","author":"T Brummaier","year":"2013","unstructured":"Brummaier T, Pohanka E, Studnicka-Benke A, et al. Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med. 2013;24(7):590\u20136.","journal-title":"Eur J Intern Med."},{"issue":"7","key":"112_CR2","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc053503","volume":"354","author":"FB Karassa","year":"2006","unstructured":"Karassa FB. Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis. N Engl J Med. 2006;354(7):764\u20135.","journal-title":"N Engl J Med."},{"issue":"25","key":"112_CR3","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med."},{"issue":"3","key":"112_CR4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"112_CR5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","volume":"44","author":"ME Jonge de","year":"2005","unstructured":"de Jonge ME, Huitema AD, Rodenhuis S, et al. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135\u201364.","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"112_CR6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.30296","volume":"63","author":"G Guenno Le","year":"2011","unstructured":"Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011;63(5):1435\u201345.","journal-title":"Arthritis Rheum."},{"issue":"9","key":"112_CR7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3899\/jrheum.150065","volume":"42","author":"N Yilmaz","year":"2015","unstructured":"Yilmaz N, Emmungil H, Gucenmez S, et al. Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases. J Rheumatol. 2015;42(9):1661\u20136.","journal-title":"J Rheumatol."},{"issue":"5","key":"112_CR8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477\u201384.","journal-title":"Ann Intern Med."},{"issue":"4 Pt 2","key":"112_CR9","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.juro.2015.11.035","volume":"195","author":"D Johnston","year":"2016","unstructured":"Johnston D, Schurtz E, Tourville E, et al. Risk factors associated with severity and outcomes in pediatric patients with hemorrhagic cystitis. J Urol. 2016;195(4 Pt 2):1312\u20137.","journal-title":"J Urol."},{"issue":"3","key":"112_CR10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0090-4295(82)90633-1","volume":"20","author":"MJ Droller","year":"1982","unstructured":"Droller MJ, Saral R, Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology. 1982;20(3):256\u20138.","journal-title":"Urology."},{"issue":"2","key":"112_CR11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-014-2748-2","volume":"34","author":"J Li","year":"2015","unstructured":"Li J, Dai G, Zhang Z. General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade-a single-center retrospective study. Clin Rheumatol. 2015;34(2):273\u20138.","journal-title":"Clin Rheumatol."},{"issue":"7","key":"112_CR12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1191\/096120399678840837","volume":"8","author":"TM Chan","year":"1999","unstructured":"Chan TM, Li FK, Hao WK, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus. 1999;8(7):545\u201351.","journal-title":"Lupus."},{"issue":"13","key":"112_CR13","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0961203311416034","volume":"20","author":"HS Koo","year":"2011","unstructured":"Koo HS, Kim YC, Lee SW, et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus. 2011;20(13):1442\u20139.","journal-title":"Lupus."},{"issue":"5","key":"112_CR14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","volume":"43","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener\u2019s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021\u201332.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"112_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477\u201384.","journal-title":"Ann Intern Med."},{"issue":"7","key":"112_CR16","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","volume":"50","author":"K Takada","year":"2004","unstructured":"Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 2004;50(7):2202\u201310.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"112_CR17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","volume":"18","author":"C Ekhart","year":"2008","unstructured":"Ekhart C, Doodeman VD, Rodenhuis S, et al. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008;18(6):515\u201323.","journal-title":"Pharmacogenet Genomics."},{"issue":"4","key":"112_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","volume":"62","author":"S Zhong","year":"2006","unstructured":"Zhong S, Huang M, Yang X, et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol. 2006;62(4):457\u201372.","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"112_CR19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","volume":"18","author":"C Ekhart","year":"2008","unstructured":"Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008;18(11):1009\u201315.","journal-title":"Pharmacogenet Genomics."},{"key":"112_CR20","first-page":"163","volume":"03","author":"C Lingyan","year":"2014","unstructured":"Lingyan C, Xueding W, Li Jiali, et al. Relationship between aldehyde dehydrogenase polymorphisms and cyclophosphamide-induced adverse effects in patients with systemic lupus erythematosus. Chin J Clin Pharmacol. 2014;03:163\u20136.","journal-title":"Chin J Clin Pharmacol."},{"issue":"8","key":"112_CR21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbmt.2013.05.014","volume":"19","author":"RQ Kloos","year":"2013","unstructured":"Kloos RQ, Boelens JJ, de Jong TP, et al. Hemorrhagic cystitis in a cohort of pediatric transplantations: incidence, treatment, outcome, and risk factors[J]. Biol Blood Marrow Transplant. 2013;19(8):1263\u20136.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"112_CR22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.bbmt.2005.06.007","volume":"11","author":"E Gorczynska","year":"2005","unstructured":"Gorczynska E, Turkiewicz D, Rybka K, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11(10):797\u2013804.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"112_CR23","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1083-8791(03)00269-6","volume":"9","author":"GA Hale","year":"2003","unstructured":"Hale GA, Rochester RJ, Heslop HE, et al. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant. 2003;9(11):698\u2013705.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"112_CR24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.juro.2008.10.037","volume":"181","author":"JR Kaplan","year":"2009","unstructured":"Kaplan JR, Wolf JJ. Efficacy and survival associated with cystoscopy and clot evacuation for radiation or cyclophosphamide induced hemorrhagic cystitis. J Urol. 2009;181(2):641\u20136.","journal-title":"J Urol."},{"issue":"5","key":"112_CR25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","volume":"43","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener\u2019s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021\u201332.","journal-title":"Arthritis Rheum."},{"issue":"7","key":"112_CR26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","volume":"125","author":"MF Gourley","year":"1996","unstructured":"Gourley MF, Austin HR, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549\u201357.","journal-title":"Ann Intern Med."},{"issue":"1","key":"112_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","volume":"62","author":"PA Monach","year":"2010","unstructured":"Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9\u201321.","journal-title":"Arthritis Rheum."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-017-0112-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-017-0112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-017-0112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T08:46:12Z","timestamp":1503477972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-017-0112-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1007\/s40801-017-0112-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2017,6,23]]}}}